{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:55:08Z","timestamp":1793994908554,"version":"4.8.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ricerca Corrente funding from the Italian Ministry of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04672-x","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:23:07Z","timestamp":1782217387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-844X","authenticated-orcid":false,"given":"Elena","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0983-563X","authenticated-orcid":false,"given":"Elisa","family":"Ortolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-6859","authenticated-orcid":false,"given":"Stefano","family":"Cavalieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-8687","authenticated-orcid":false,"given":"Elena","family":"Tamborini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4406-8245","authenticated-orcid":false,"given":"Federica","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6572-614X","authenticated-orcid":false,"given":"Iolanda","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0582-6170","authenticated-orcid":false,"given":"Luca","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-7715","authenticated-orcid":false,"given":"Biagio","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-139X","authenticated-orcid":false,"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9307-3975","authenticated-orcid":false,"given":"Giuseppina","family":"Calareso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9111-4326","authenticated-orcid":false,"given":"Monica","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Platini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7616-5125","authenticated-orcid":false,"given":"Cristiana","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-2275","authenticated-orcid":false,"given":"Salvatore","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0188-9759","authenticated-orcid":false,"given":"Carlo","family":"Resteghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4239-8072","authenticated-orcid":false,"given":"Arianna","family":"Ottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1139-5873","authenticated-orcid":false,"given":"Francesca","family":"Caspani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-5301","authenticated-orcid":false,"given":"Imperia","family":"Nuzzolese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4345-3355","authenticated-orcid":false,"given":"Achille","family":"Bottiglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4637-9821","authenticated-orcid":false,"given":"Giacomo","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3328-7282","authenticated-orcid":false,"given":"Daria Maria","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-7172","authenticated-orcid":false,"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-4118","authenticated-orcid":false,"given":"Lisa","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-1321","authenticated-orcid":false,"given":"Maria Grazia","family":"Daidone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-2580","authenticated-orcid":false,"given":"Laura Deborah","family":"Locati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"4672_CR1","doi-asserted-by":"publisher","first-page":"104766","DOI":"10.1016\/j.oraloncology.2020.104766","volume":"108","author":"L Locati","year":"2020","unstructured":"L. Locati, S. Cavalieri, L. Dal Maso et al., Rare thyroid malignancies in Europe: Data from the information network on rare cancers in Europe (RARECAREnet). Oral Oncol. 108, 104766 (2020). https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104766","journal-title":"Oral Oncol."},{"issue":"1","key":"4672_CR2","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41467-023-36922-1","volume":"14","author":"V Veschi","year":"2023","unstructured":"V. Veschi, A. Turdo, C. Modica et al., Recapitulating thyroid cancer histotypes through engineering embryonic stem cells. Nat. Commun. 14(1), 1351 (2023). https:\/\/doi.org\/10.1038\/s41467-023-36922-1","journal-title":"Nat. Commun."},{"issue":"12","key":"4672_CR3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"S. Filetti, C. Durante, D. Hartl et al., Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30(12), 1856\u20131883 (2019). https:\/\/doi.org\/10.1093\/annonc\/mdz400","journal-title":"Ann. Oncol."},{"issue":"5","key":"4672_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1089\/thy.2016.0395","volume":"27","author":"SN Rao","year":"2017","unstructured":"S.N. Rao, M. Zafereo, R. Dadu et al., Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 27(5), 672\u2013681 (2017). https:\/\/doi.org\/10.1089\/thy.2016.0395","journal-title":"Thyroid"},{"issue":"13","key":"4672_CR5","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","volume":"24","author":"N Pozdeyev","year":"2018","unstructured":"N. Pozdeyev, L.M. Gay, E.S. Sokol et al., Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin. Cancer Res. 24(13), 3059\u20133068 (2018). https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0373","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"4672_CR6","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1038\/s41379-020-0638-5","volume":"33","author":"YH Chu","year":"2020","unstructured":"Y.H. Chu, L.J. Wirth, A.A. Farahani et al., Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. Mod. Pathol. 33(12), 2458\u20132472 (2020). https:\/\/doi.org\/10.1038\/s41379-020-0638-5","journal-title":"Mod. Pathol."},{"issue":"1","key":"4672_CR7","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","volume":"10","author":"SK Yoo","year":"2019","unstructured":"S.K. Yoo, Y.S. Song, E.K. Lee et al., Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nat. Commun. 10(1), 2764 (2019). https:\/\/doi.org\/10.1038\/s41467-019-10680-5","journal-title":"Nat. Commun."},{"issue":"3","key":"4672_CR8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s12020-022-03031-w","volume":"76","author":"PP Qiao","year":"2022","unstructured":"P.P. Qiao, K.S. Tian, L.T. Han et al., Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma. Endocrine. 76(3), 660\u2013670 (2022). https:\/\/doi.org\/10.1007\/s12020-022-03031-w","journal-title":"Endocrine"},{"issue":"6","key":"4672_CR9","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1210\/jc.2016-3756","volume":"102","author":"AV Chintakuntlawar","year":"2017","unstructured":"A.V. Chintakuntlawar, K.M. Rumilla, C.Y. Smith et al., Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. J. Clin. Endocrinol. Metab. 102(6), 1943\u20131950 (2017). https:\/\/doi.org\/10.1210\/jc.2016-3756","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"4672_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"V. Subbiah, R.J. Kreitman, Z.A. Wainberg et al., Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann. Oncol. 33(4), 406\u2013415 (2022). https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014","journal-title":"Ann. Oncol."},{"issue":"23","key":"4672_CR11","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"J. Capdevila, L.J. Wirth, T. Ernst et al., PD-1 Blockade in Anaplastic Thyroid Carcinoma. JCO. 38(23), 2620\u20132627 (2020). https:\/\/doi.org\/10.1200\/JCO.19.02727","journal-title":"JCO"},{"issue":"15suppl","key":"4672_CR12","doi-asserted-by":"publisher","first-page":"6513","DOI":"10.1200\/JCO.2020.38.15_suppl.6513","volume":"38","author":"JH Lorch","year":"2020","unstructured":"J.H. Lorch, J.A. Barletta, M. Nehs et al., A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC). JCO. 38(15suppl), 6513\u20136513 (2020). https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.6513","journal-title":"JCO"},{"key":"4672_CR13","doi-asserted-by":"publisher","first-page":"S1294","DOI":"10.1016\/j.annonc.2022.07.1725","volume":"33","author":"JC Castillon","year":"2022","unstructured":"J.C. Castillon, M. Plana, B. Castelo et al., 1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial. Ann. Oncol. 33, S1294\u2013S1295 (2022). https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1725","journal-title":"Ann. Oncol."},{"issue":"Suppl 7","key":"4672_CR14","doi-asserted-by":"publisher","first-page":"S750","DOI":"10.1016\/annonc\/annonc1077","volume":"33","author":"C Dierks","year":"2022","unstructured":"C. Dierks, J. Ruf, J. Seufert, M. Kreissl, C. Klein, C. Spitzweg, 1646MO - Phase II ATLEP trial: Final results for lenvatinib\/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. Ann. Oncol. 33(Suppl 7), S750\u2013S757 (2022). https:\/\/doi.org\/10.1016\/annonc\/annonc1077","journal-title":"Ann. Oncol."},{"key":"4672_CR15","doi-asserted-by":"publisher","first-page":"S624","DOI":"10.1016\/j.annonc.2021.08.710","volume":"32","author":"E Grande","year":"2021","unstructured":"E. Grande, R. Garcia-Carbonero, A. Teule et al., 575TiP Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial \/ GETNE-T1914). Ann. Oncol. 32, S624\u2013S625 (2021). https:\/\/doi.org\/10.1016\/j.annonc.2021.08.710","journal-title":"Ann. Oncol."},{"issue":"15suppl","key":"4672_CR16","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1200\/JCO.2020.38.15","volume":"38","author":"ME Cabanillas","year":"2020","unstructured":"M.E. Cabanillas, R. Dadu, R. Ferrarotto et al., Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). JCO. 38(15suppl), 6514\u20136514 (2020). https:\/\/doi.org\/10.1200\/JCO.2020.38.15","journal-title":"JCO"},{"key":"4672_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2022.12.002","volume":"180","author":"LD Locati","year":"2023","unstructured":"L.D. Locati, E. Colombo, M. Dedecjus et al., Current picture of anaplastic thyroid cancer patients\u2019 care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups. Eur. J. Cancer. 180, 146\u2013154 (2023). https:\/\/doi.org\/10.1016\/j.ejca.2022.12.002","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"4672_CR18","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","volume":"33","author":"S Filetti","year":"2022","unstructured":"S. Filetti, C. Durante, D.M. Hartl et al., ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann. Oncol. 33(7), 674\u2013684 (2022). https:\/\/doi.org\/10.1016\/j.annonc.2022.04.009","journal-title":"Ann. Oncol."},{"issue":"3","key":"4672_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"K.C. Bible, E. Kebebew, J. Brierley et al., 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer: American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force. Thyroid. 31(3), 337\u2013386 (2021). https:\/\/doi.org\/10.1089\/thy.2020.0944","journal-title":"Thyroid"},{"issue":"8","key":"4672_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","volume":"20","author":"RI Haddad","year":"2022","unstructured":"R.I. Haddad, L. Bischoff, D. Ball et al., Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 20(8), 925\u2013951 (2022). https:\/\/doi.org\/10.6004\/jnccn.2022.0040","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"8","key":"4672_CR21","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"J. Pascual, G. Attard, F.C. Bidard et al., ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 33(8), 750\u2013768 (2022). https:\/\/doi.org\/10.1016\/j.annonc.2022.05.520","journal-title":"Ann. Oncol."},{"key":"4672_CR22","doi-asserted-by":"publisher","first-page":"e2100512","DOI":"10.1200\/PO.21.00512","volume":"6","author":"MA Gouda","year":"2022","unstructured":"M.A. Gouda, H.J. Huang, S.A. Piha-Paul et al., Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol. 6, e2100512 (2022). https:\/\/doi.org\/10.1200\/PO.21.00512","journal-title":"JCO Precis Oncol."},{"issue":"6","key":"4672_CR23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/thy.2022.0704","volume":"33","author":"ML Gild","year":"2023","unstructured":"M.L. Gild, M. Bullock, V. Tsang, R.J. Clifton-Bligh, B.G. Robinson, L.J. Wirth, Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics. Thyroid. 33(6), 682\u2013690 (2023). https:\/\/doi.org\/10.1089\/thy.2022.0704","journal-title":"Thyroid"},{"issue":"1","key":"4672_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/thy.2016.0076","volume":"27","author":"VC Sandulache","year":"2017","unstructured":"V.C. Sandulache, M.D. Williams, S.Y. Lai et al., Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 27(1), 81\u201387 (2017). https:\/\/doi.org\/10.1089\/thy.2016.0076","journal-title":"Thyroid"},{"key":"4672_CR25","doi-asserted-by":"publisher","unstructured":"P.C. Iyer, G.J. Cote, T. Hai et al., Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precis Oncol. 2018;Dec 20;2:PO.18.00173. https:\/\/doi.org\/10.1200\/PO.18.00173","DOI":"10.1200\/PO.18.00173"},{"issue":"8","key":"4672_CR26","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1089\/thy.2020.0296","volume":"31","author":"Y Qin","year":"2021","unstructured":"Y. Qin, J.R. Wang, Y. Wang et al., Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid. 31(8), 1235\u20131243 (2021). https:\/\/doi.org\/10.1089\/thy.2020.0296","journal-title":"Thyroid"},{"issue":"2","key":"4672_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/01.pas.0000176432.73455.1b","volume":"30","author":"AJ Adeniran","year":"2006","unstructured":"A.J. Adeniran, Z. Zhu, M. Gandhi et al., Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am. J. Surg. Pathol. 30(2), 216\u2013222 (2006). https:\/\/doi.org\/10.1097\/01.pas.0000176432.73455.1b","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"4672_CR28","doi-asserted-by":"publisher","first-page":"e001501","DOI":"10.1136\/jitc-2020-001501","volume":"8","author":"EP Hoefsmit","year":"2020","unstructured":"E.P. Hoefsmit, E.A. Rozeman, T.M. Van et al., Comprehensive analysis of cutaneous and uveal melanoma liver metastases. J. Immunother Cancer. 8(2), e001501 (2020). https:\/\/doi.org\/10.1136\/jitc-2020-001501","journal-title":"J. Immunother Cancer"},{"issue":"11","key":"4672_CR29","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.ejso.2021.05.039","volume":"47","author":"L Gau","year":"2021","unstructured":"L. Gau, M. Ribeiro, B. Pereira et al., Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis. Eur. J. Surg. Oncol. 47(11), 2722\u20132733 (2021). https:\/\/doi.org\/10.1016\/j.ejso.2021.05.039","journal-title":"Eur. J. Surg. Oncol."},{"issue":"6","key":"4672_CR30","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.18632\/aging.203980","volume":"14","author":"JZ Cao","year":"2022","unstructured":"J.Z. Cao, G.S. Yao, F. Liu et al., TP53\/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types. Aging (Albany NY). 14(6), 2868\u20132879 (2022). https:\/\/doi.org\/10.18632\/aging.203980","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"4672_CR31","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/thy.2023.0573","volume":"34","author":"S Hamidi","year":"2024","unstructured":"S. Hamidi, P. Iyer, R. Dadu et al., Checkpoint Inhibition in Addition to Dabrafenib\/Trametinib for BRAFV600E Mutated Anaplastic Thyroid Carcinoma. Thyroid. Mar; 34(3), 336\u2013346 (2024). https:\/\/doi.org\/10.1089\/thy.2023.0573","journal-title":"Thyroid"},{"issue":"1","key":"4672_CR32","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/j.clon.2022.10.017","volume":"35","author":"C Lorimer","year":"2023","unstructured":"C. Lorimer, L. Cheng, R. Chandler et al., Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres. Clin. Oncol. (R Coll. Radiol). 35(1), e60\u2013e66 (2023). https:\/\/doi.org\/10.1016\/j.clon.2022.10.017","journal-title":"Clin. Oncol. (R Coll. Radiol)"},{"issue":"1","key":"4672_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/thy.2017.0285","volume":"28","author":"PC Iyer","year":"2018","unstructured":"P.C. Iyer, R. Dadu, R. Ferrarotto et al., Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid. 28(1), 79\u201387 (2018). https:\/\/doi.org\/10.1089\/thy.2017.0285","journal-title":"Thyroid"},{"issue":"6","key":"4672_CR34","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1158\/1535-7163.MCT-21-0950","volume":"21","author":"JJ Adashek","year":"2022","unstructured":"J.J. Adashek, A.K. Menta, N.K. Reddy, A.P. Desai, J. Roszik, V. Subbiah, Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors. Mol. Cancer Ther. 21(6), 871\u2013878 (2022). https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0950","journal-title":"Mol. Cancer Ther."},{"key":"4672_CR35","doi-asserted-by":"publisher","unstructured":"A. Jannin, F. Giudici, de la C. Fouchardi\u00e8re, E.N.D.O.C.A.N.-T.U.T.H.Y.R.E.F. Network et al., Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network. Thyroid. 2023;33(10):1190\u20131200. Erratum in: Thyroid. 2024;34(1):140. https:\/\/doi.org\/10.1089\/thy.2023.0164.correx","DOI":"10.1089\/thy.2023.0164.correx"},{"issue":"11","key":"4672_CR36","doi-asserted-by":"publisher","first-page":"105856","DOI":"10.1016\/j.esmoop.2025.105856","volume":"10","author":"E Colombo","year":"2025","unstructured":"E. Colombo, S. Cavalieri, A. Vingiani et al., Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study. ESMO Open. 10(11), 105856 (2025). https:\/\/doi.org\/10.1016\/j.esmoop.2025.105856","journal-title":"ESMO Open."},{"issue":"9","key":"4672_CR37","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","volume":"6","author":"V Subbiah","year":"2020","unstructured":"V. Subbiah, C. Baik, J.M. Kirkwood, Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 6(9), 797\u2013810 (2020). https:\/\/doi.org\/10.1016\/j.trecan.2020.05.009","journal-title":"Trends Cancer"},{"issue":"9","key":"4672_CR38","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1089\/thy.2019.0514","volume":"30","author":"ME Cabanillas","year":"2020","unstructured":"M.E. Cabanillas, R. Dadu, P. Iyer et al., Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid. 30(9), 1288\u20131296 (2020). https:\/\/doi.org\/10.1089\/thy.2019.0514","journal-title":"Thyroid"},{"key":"4672_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fonc.2019.00268","volume":"9","author":"SA Lebker","year":"2019","unstructured":"S.A. Lebker, S.A. Koepsell, Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies. Front. Oncol. 9, 268 (2019). https:\/\/doi.org\/10.3389\/fonc.2019.00268","journal-title":"Front. Oncol."},{"issue":"3","key":"4672_CR40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","volume":"35","author":"MA Gouda","year":"2024","unstructured":"M.A. Gouda, F. Janku, A. Wahida et al., Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST). Ann. Oncol. 35(3), 267\u2013275 (2024). https:\/\/doi.org\/10.1016\/j.annonc.2023.12.007","journal-title":"Ann. Oncol."},{"issue":"4","key":"4672_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.annonc.2023.01.008","volume":"34","author":"A Bayle","year":"2023","unstructured":"A. Bayle, L. Belcaid, M. Aldea et al., Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study. Ann. Oncol. 34(4), 389\u2013396 (2023). https:\/\/doi.org\/10.1016\/j.annonc.2023.01.008","journal-title":"Ann. Oncol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04672-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04672-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04672-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:23:08Z","timestamp":1782217388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04672-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4672"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04672-x","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: S. Cavalieri: occasional fees for participation as a speaker at conferences\/congresses from AccMed; support for attending meetings and\/or travel from AccMed, MultiMed Engineers srl, Care Insight sas. L. Licitra: Consulting fees from MSD IT; Merck Serono Spa Healthcare Professional; Merck Healthcare KGaA; GSK, F. Hoffman La Roche Ltd; EMD Serono Research & Development Institute, Inc.; Boehringer sIngelheim International GmbH; Simon-Kucher & Partners Strategy & Marketing Consultants; Rgenta Therapeutics, Inc; Alentis Therapeutics AG; MedImmune Limited. Payment or honoraria for lectures, presentations, speakers bureau, manuscript writing or educational events: Merck Serono Spa; MSD IT; Merck Healthcare KGaA; Adlai Nortye; Bristol Myers Squibb; ALTIS Omnia Pharma Service Srl Support for attending meetings and\/or travel: TAE Life Science. Participation on a Data Safety Monitoring Board or Advisory Board: Merck Healthcare KGaA.; Merck & Co. Inc; a; MSD IT; EMD Serono Research & Development Institute, Inc.; F. Hoffman-La Roche Ltd; Janssen Research & Development, LLC; Seagen International GmbH; Genmab US, Inc.; Astrazeneca UK limited; Abbvie Srl; Simon-Kucher & Partners Strategy & Marketing Consultants; Purple Biotech, Ltd. Grants or contracts from any entity (research funds for clinical trials): Adlai Nortye; Astrazeneca; BMS; Debiopharm International SA; Eisai; Eli Lilly and Company; Exelixis; Hoffman-La Roche Ltd; Isa Therapeutics; Kura Oncology; Merck Serono; MSD; Merck Sharp&Dome Corp; Nektar Therapeutics; Novartis; Regeneron; Roche; Sanofi; Syneos; Sun Pharmaceutica; Incyte Biosciences International S\u00e0rl; Gilead Sciences, Inc.; Genmab; Merck Healthcare KGaA. LD. Locati: Advisory Board EISAI, MSD, Merck, Eli Lilly, Bayer, Roche, Ipsen, Novartis, Seagen, Gentili srl; travel grant: Gilead. B. Paolini: Advisory Board EISAI. Honoraria for lectures and presentations: MSD, AstraZeneca. G. Pruneri: personal fees from Novartis, Illumina, Roche, Eli Lilly and Company. C. Resteghini: honoraria from SunPharma. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"213"}}